Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (H5N1) in Adults
NCT00620815Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Primary completion
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MF59 + eTIV + H5N1 in influenza A virus H5N1 subtype infection (H5N1), influenza, sponsored by Novartis. Started Nov 2007; status: completed.
02
Drugs
MF59 + eTIV + H5N1
03
Conditions
influenza A virus H5N1 subtype infection (H5N1)influenza
Beyond the preview
Go deeper on NCT00620815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00620815.